Multiparametric Magnetic Resonance Imaging in Evaluation of Clinically Significant Prostate Cancer

Sarang M. Ingole¹  Rajeev U. Mehta¹  Zubair N. Kazi¹  Rutuja V. Bhuyar¹

¹Department of Imaging Sciences and Pathology, Saifee Hospital, Mumbai, Maharashtra, India

Abstract

Aim In this prospective study, we evaluate the role of multiparametric magnetic resonance imaging (mp-MRI) in the assessment of clinically significant prostate cancer at 1.5 T without endorectal coil (ERC).

Materials and Methods Forty-five men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] level > 4 ng/mL, hard prostate on digital rectal examination, and suspicious area at transrectal ultrasound [TRUS]) were evaluated using the mp-MRI protocol over a period of 24 months. All cases were interpreted using the Prostate Imaging Reporting and Data System (PI-RADS) version 2 guidelines and correlated with histopathology.

Statistical Analysis Used A chi-squared test was used for analysis of nominal/categorical variables and receiver operating characteristic (ROC) curve and one-way analysis of variance (ANOVA) test for continuous variables.

Results The mean age was 67 years and the mean PSA was 38.2 ng/mL. Eighty percent had prostate cancer and 20% were benign (11% benign prostatic hyperplasia [BPH] and 9% chronic prostatitis). Eighty-six percent of all malignancies were in the peripheral zone. The PI-RADS score for T2-weighted (T2W) imaging showed good sensitivity (81%) but low specificity (67%). The PI-RADS score for diffusion weighted imaging (DWI) with sensitivity of 92% and specificity of 78% had a better accuracy overall than T2W imaging alone. The mean apparent diffusion coefficient (ADC) value (×10⁻⁶ mm²/s) was 732 ± 160 in prostate cancer, 1,009 ± 161 in chronic prostatitis, 1,142 ± 82 in BPH, and 663 in a single case of granulomatous prostatitis. Low ADC values (<936) have shown good correlation (area under curve [AUC]: 0.87) with the presence of cancer foci. Inverse correlation was observed between Gleason scores and ADC values. Dynamic contrast-enhanced (DCE) imaging has shown 100% sensitivity/negative predictive value (NPV), but moderate specificity (67%) in predicting malignancy. The final PI-RADS score had 100% sensitivity and NPV with good overall positive predictive value (PPV) of 95%.

Conclusions T2W imaging and DWI remain the mainstays in diagnosis of prostate cancer with mp-MRI. DCE-MRI can be a problem-solving tool in case of equivocal findings. Because assessment with mp-MRI can be subjective, use of the newly developed PI-RADS version 2 scoring system is helpful in accurate interpretation.
Introduction

Prostate cancer (PCa) is the second most frequent malignancy (after lung cancer) in men and the fifth leading cause of death worldwide. Detection and clinical staging of PCa currently includes a prostate-specific antigen (PSA) test, a digital rectal examination (DRE), and a transrectal ultrasound (TRUS) guided prostate biopsy. However, the biology of PCa is indolent, and incidence does not reflect mortality. Also, the current diagnostic pathway for PCa has resulted in overdiagnosis and subsequent overtreatment as well as underdiagnosis and missed diagnoses in many men. This has led to reframed screening guidelines pivoting around serum PSA and conceptualizing clinically significant PCa (CSC). In 2012, European Society of Urogenital Radiology (ESUR) prostate MRI working group developed and published Prostate Imaging Reporting and Data System version 1 (PI-RADS v1) for standardizing the acquisition, interpretation, and reporting of prostate MRI. Although PI-RADS v1 served this important purpose, its adoption was limited because of potential weaknesses in the proposed reporting system and ongoing evolution in the field itself. In 2015, American College of Radiology published PI-RADS v2, which addressed many of the shortcomings associated with PI-RADS v1 by providing specific algorithm for deriving an overall assessment on the basis of a lesion’s individual scores on T2-weighted imaging (T2WI), diffusion weighted imaging (DWI), and dynamic contrast-enhanced MRI (DCE-MRI). In developing countries, widespread availability of 3-T MRI is still a challenge and cost of upgrading from the existing 1.5 to 3 T or use of endorectal coil (ERC) does not justify its routine use.

The scope of the current study was to evaluate the role of mp-MRI-based PI-RADS v2 for the assessment of clinically significant PCa at 1.5 T without using ERC.

Materials and Methods

This prospective study was conducted in tertiary care hospital and approved by the institutional review board.

Study Population

A total of 45 male patients within the study period from 2015 to 2017 with strong clinical suspicion of PCa (lower urinary tract symptoms and DRE) and raised PSA value (>4 ng/mL) or TRUS biopsy–proven cases of PCa were evaluated. Patients who had undergone prostate biopsy less than 6 weeks before the MRI, post-hormonal/radiation therapy, and who had general contraindication for MRI were excluded from study.

Mp-MRI Protocol

MRI was performed on MAGNETOM Avanto (Siemens Healthcare, Erlangen, Germany), Syngo MR 2004 V, 1.5-T 18-channel equipment. A dedicated body matrix coil was used for imaging the prostate. The imaging protocol used is given in detail in Table 1.

All images were analyzed by two radiologists with >10 and >20 years of experience.

The following assessments were made: volume of the prostate gland, distribution of lesions (focal or diffuse), and location of the lesion either in the central gland (transition/central zone) or the peripheral gland (peripheral zone [PZ]) or both.

The prostate was viewed in T1WI, T2WI, and DWI sequences with calculation of ADC values using the ADC maps and any abnormality was identified. When multiple lesions were noted, the most representative lesion or the largest of the lesions was taken as the index lesion. The PI-RADS score was assigned to the index lesion on T2WI and DWI separately. In addition, early enhancement on DCE-MRI and Cho + Cr/Ci ratio on magnetic resonance spectroscopy (MRS) in the index lesion was assigned to the index lesion on T2WI and DWI separately.

Table 1

<table>
<thead>
<tr>
<th>Image plane</th>
<th>Acquisition scheme</th>
<th>Slice thickness (mm)</th>
<th>TR (ms)</th>
<th>TE (ms)</th>
<th>FOV (mm)</th>
<th>Matrix</th>
<th>Flip angle</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2 axial</td>
<td>Fast spin echo</td>
<td>3</td>
<td>4,100</td>
<td>102</td>
<td>220/100</td>
<td>320 × 224</td>
<td>150</td>
</tr>
<tr>
<td>T2 coronal</td>
<td>Fast spin echo</td>
<td>3</td>
<td>4,760</td>
<td>102</td>
<td>220/100</td>
<td>320 × 224</td>
<td>150</td>
</tr>
<tr>
<td>T2 sagittal</td>
<td>Fast spin echo</td>
<td>3</td>
<td>4,500</td>
<td>96</td>
<td>220/100</td>
<td>320 × 224</td>
<td>150</td>
</tr>
<tr>
<td>DWI</td>
<td>Echo planar imaging (EPI) b value = 50,400,800</td>
<td>3</td>
<td>3,700</td>
<td>80</td>
<td>340/100</td>
<td>192 × 192</td>
<td>–</td>
</tr>
<tr>
<td>T1 axial</td>
<td>Fast Spin echo</td>
<td>3</td>
<td>720</td>
<td>11</td>
<td>220/100</td>
<td>320 × 224</td>
<td>150</td>
</tr>
<tr>
<td>T1WDCE</td>
<td>3D fast spoiled gradient recalled (FSPGR-VIBE)*</td>
<td>–</td>
<td>4.7</td>
<td>1.6</td>
<td>260/100</td>
<td>138 × 192</td>
<td>12</td>
</tr>
<tr>
<td>STIR axial</td>
<td>IR</td>
<td>3</td>
<td>3,100</td>
<td>55</td>
<td>220/100</td>
<td>179 × 256</td>
<td>150</td>
</tr>
</tbody>
</table>

Abbreviations: DCE, dynamic contrast-enhanced; DWI, diffusion weighted imaging; FOV, field of view; IR, inversion recovery; STIR, short tau inversion recovery; TE, echo time; TR, repetition time; T1W, T1-weighted; VIBE, volumetric interpolated breath-hold examination.

*Obtained immediately before, during, and after bolus administration of 0.1 mmol/kg body weight MultiHance (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) at a rate of 2 mL/s using a power injector Medrad Spectris Solaris EP MR injection system (Bayer Vital GmbH, Bayer HealthCare, Leverkusen, Germany) followed by 15-ml saline flush. The acquisitions were obtained every 5 seconds.
lesion was also studied. In equivocal cases on DWI for lesions in the PZ, DCE curve was referred to and a final PI-RADS score was given, whereas in equivocal cases for lesion in the transition zone (TZ), the DWI score was referred to and accordingly the final PI-RADS score was given (►Figs. 1 and 2). In addition, assessment of pelvic soft-tissue structures was done for the involvement of extra prostatic/capsular extension (ECE), seminal vesicles (SV), neurovascular bundle (NVB), and pelvic lymph nodes (LN).

All patients underwent 12-core TRUS-guided biopsy with which individual and combined parameters on various MRI sequences and PI-RADS v2 score were correlated.

Biopsy was performed with each core from the medial and lateral aspects of the gland at the apex, mid-gland, and base in right and left halves. Biopsy specimens were fixed in formaldehyde, embedded in paraffin, and stained with hematoxylin and eosin. Lesions were reported as cancer (and assigned Gleason scores) or as benign tissue for each core. The pathologists were blinded to the results of MRI examination. The index lesion was plotted on PI-RADS sector map and histopathology finding of the corresponding core—benign prostatic hyperplasia (BPH), prostatitis, cancer with its Gleason score—was taken into consideration. Ten patients of this cohort also underwent radical prostatectomy at our institute, with which staging parameters were correlated.

Statistical Analysis

Continuous variables were summarized as mean and standard deviations, and nominal/categorical variables as proportions (%). Chi-squared test was used for analysis of nominal/categorical variables. Receiver operating characteristic (ROC) curve and one-way analysis of variance (ANOVA) test were used for continuous variables. Diagnostic accuracy for various sequences of MRI was assessed by means of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A \( p < 0.05 \) was considered significant. IBM SPSS Statistics 22.0 and MedCalc v12.5 were used for all statistical calculations.

Results

In our study, the mean age of the study population was 67 years with majority of patients belonging to the 65 to 74 years age group (52%). The mean PSA was 38.2 ng/mL with most of the malignant lesions belonging to the high-suspicion group (>10 ng/mL; ◄Table 2). However, no significant correlation between rising PSA values and PCa could be conclusively established.

Of the 45 patients evaluated in our study, 26 (57%) had focal lesions, of which 22 were malignant and 4 were benign. The remaining 19 patients (43%) had diffuse lesions, of which 14 were malignant and 5 were benign. PCa was seen in ~84% of focal lesions (\( n = 22 \)) and 73% of diffuse lesions (\( n = 14 \)); no statistically significance difference was found in the distribution of lesions.

Most of the cases in our study cohort were distributed in the PZ (51%, \( n = 23 \)); -33% (\( n = 15 \)) of lesions involved both the PZ and the TZ and 16% (\( n = 7 \)) were seen only in the TZ. Approximately 86% (\( n = 31 \)) of malignancies involved the PZ, whereas only 13% (\( n = 5 \)) of PCa were seen in the TZ.

<table>
<thead>
<tr>
<th>Peripheral Zone Lesion</th>
<th>Final PIRADS Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 No abnormality (i.e., normal) on ADC and high b-value DWI</td>
<td>1</td>
</tr>
<tr>
<td>2 Indistinct hypointense on ADC</td>
<td>2</td>
</tr>
<tr>
<td>3 Focal mildly/moderately hypointense on ADC and isointense/mildly hypointense on high b-value DWI.</td>
<td>3</td>
</tr>
<tr>
<td>4 Focal markedly hypointense on ADC and markedly hypointense on high b-value DWI; &lt;1.5cm in greatest dimension</td>
<td>4</td>
</tr>
<tr>
<td>5 Same as 4 but ≥1.5cm in greatest dimension or definite extraprostatic extension/invasive behavior</td>
<td>5</td>
</tr>
</tbody>
</table>

*Negative*: No early enhancement, or diffuse enhancement not corresponding to a focal finding on T2W and/or DWI or focal enhancement corresponding to a lesion demonstrating features of BPH on T2WI

*Positive*: Focal, and; earlier than or contemporaneously with enhancement of adjacent

Fig. 1 Flowchart for peripheral zone lesion. ADC, apparent diffusion coefficient; BPH, benign prostatic hyperplasia; DCE, dynamic contrast enhanced; DWI, diffusion weighted imaging; PI-RADS, Prostate Imaging Reporting and Data System; T2WI, T2-weighted image.
On post biopsy follow-up, 80% (n = 36) of the study cohort had PCa and 20% of cases (n = 9) were benign. Among the benign cases, 11% (n = 5) had BPH and 9% (n = 4) had chronic prostatitis, a single case (2%) of which had dense granulomatous prostatitis with microabscesses (►Table 3).

In our study, of the five cases that were given a PI-RADS score of 2 (clinically significant cancer unlikely to be present), based on T2WI, only one turned out to be malignant. Of the eight cases reported as PI-RADS 3 (equivocal presence of clinically significant cancer), six turned out to be malignant. Of the nine cases reported as PI-RADS 4 (clinically significant cancer likely to be present), two turned out to be benign. Twenty-two of 23 cases reported as PI-RADS 5 (clinically significant malignancy highly likely to be present) turned out to be malignant (►Table 4). PI-RADS score for T2WI showed good sensitivity (81%) but low specificity (67%) with good PPV (91%) for PI-RADS scores 4 and 5.

On DWI, none of the six cases that were given a PI-RADS score of 2 (clinically significant cancer unlikely to be present) turned out to be malignant. Of the four cases reported as PI-RADS 3 (equivocal presence of clinically significant cancer), three were malignant. Of the 10 cases reported as PI-RADS 4 (clinically significant cancer likely to be present), only 1 was benign. Twenty-four of the 25 cases reported as PI-RADS 5 (clinically significant malignancy highly likely to be present) turned out to be malignant (►Table 5). The PI-RADS scores for DWI had sensitivity of 92%, specificity of 78%, PPV of 94%, and NPV of 70%, with overall accuracy better than T2WI alone.

The malignant lesions had a mean ADC value of $732 \pm 160 \times 10^{-6} \text{ mm}^2/\text{s}$, benign prostatic hypertrophy had mean of $1,142 \pm 82 \times 10^{-6} \text{ mm}^2/\text{s}$ and chronic prostatitis had mean $1,009 \pm 161 \times 10^{-6} \text{ mm}^2/\text{s}$. However, a single case of dense granulomatous prostatitis with microabscesses had a mean ADC value of $1,349 \pm 100 \times 10^{-6} \text{ mm}^2/\text{s}$.

Table 2 Association between PSA values and histopathological interpretation

<table>
<thead>
<tr>
<th>PSA range (ng/mL)</th>
<th>Histopathology</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Benign</td>
<td>Malignant</td>
</tr>
<tr>
<td>&lt;10</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>10–20</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>&gt;20</td>
<td>3</td>
<td>18</td>
</tr>
<tr>
<td>Total</td>
<td>9</td>
<td>36</td>
</tr>
</tbody>
</table>

Abbreviation: PSA, prostate-specific antigen.
Note: $p = 0.669$ (not significant) using Pearson’s chi-squared test.

Table 3 Histopathological interpretation of lesions: frequency analysis

<table>
<thead>
<tr>
<th>Histopathological diagnosis</th>
<th>No. of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPH</td>
<td>5 (11%)</td>
</tr>
<tr>
<td>CA</td>
<td>36 (80%)</td>
</tr>
<tr>
<td>Prostatitis</td>
<td>4 (9%)</td>
</tr>
<tr>
<td>Total</td>
<td>45</td>
</tr>
</tbody>
</table>

Abbreviations: BPH, benign prostatic hyperplasia; CA, cancer.
mean ADC value of $663 \times 10^{-6}$ mm$^2$/s (Table 6). ROC curve analysis showed a statistical difference in the ADC values of benign and malignant lesions with suggested cutoff criterion of <936 (Fig. 3). In addition, inverse correlation was observed between Gleason score and ADC values in pathologically proven cases of cancer (36 cases), that is, lower the value, higher the grade of tumor (Table 7 and Fig. 4).

DCE-MRI was performed in 44 of 45 cases. In one case, DCE-MRI could not be performed due to raised serum creatinine. Thirty-eight of 44 cases showed early enhancement, of which 35 turned out to be malignant. None of the six cases that did not show early enhancement turned out to be malignant. The sensitivity and specificity of DCE-MRI for PCa diagnosis was 100% and 67%, respectively (Table 8).

Of the four cases with PI-RADS category 3 on DWI, three were in the PZ and showed early enhancement. So the final PI-RADS score was upgraded to 4 according to the new guidelines, and all of them turned out to be malignant on histopathology.

The final PI-RADS score had almost 100% sensitivity and NPV, with good overall PPV (95%). Moderate specificity (78%) may be due to few false-positive cases of chronic prostatitis and microabscesses. However, none of the malignant cases were missed in the final PI-RADS scoring (Fig. 4).

MRS was performed for 42 of 45 patients and it showed moderate sensitivity (81%) and specificity (78%), good PPV (93%), but poor NPV (53%) with suggested Cho + Cr/Ci ratio cutoff criterion >0.89 (Fig. 5).

The ROC curve analysis showed the highest area under curve (AUC) and in turn the diagnostic performance for the final PI-RADS score (0.90), which integrated the mp-MRI protocol, followed by DWI alone (0.89), T2WI alone (0.83), and MRS alone (0.82).

The role of 1.5-T MRI in staging was correlated in 10 patients who underwent radical prostatectomy at our institute. In our study, use of 1.5-T MRI without ERC has shown low sensitivity and specificity for detection of ECE and NVB involvement. However, excellent specificity was seen in detection of SV involvement and pelvic lymph nodal metastasis.

### Discussion

The worldwide PCa burden is expected to grow to 1.7 million new cases and 499,000 new deaths by 2030 simply due to the growth and aging of the global population. Although the incidence rates of PCa are considered low in Asian and North African countries, ranging from 1 to 9/100,000 persons, demographic and epidemiological transitions in developing countries like India have shown an increasing trend in the burden of various cancer cases including PCa.

Data from national cancer registries show that the incidence rates of certain cancers are on rise in India. The cancers that are showing significant increase in incidence rates include prostate, mouth, and kidney cancers in males; corpus uteri, breast, and thyroid in females; and lung cancer in both males and females. The prostate is the second leading site of cancer among males in large Indian cities like Delhi, Kolkata, Pune, and Thiruvananthapuram; third leading site of cancer in cities like Bangalore and Mumbai; and it is among the top 10 leading sites of cancers in the rest of the population based cancer registries (PBCRs) of India. The 5-year survival rate is close to 100% if the disease is diagnosed in its early stages; however, the survival rate drops to 28% if the disease is diagnosed in an advanced stage.
disease is metastatic at the time of diagnosis. So early diagnosis is pivotal in the management of PCAs.

**DRE** is only limited to detecting lesions protruding the surface of the prostate. It has a very low sensitivity of only 30% and a specificity of 40% for the diagnosis of organ-confined disease.8,9

**PSA** has been used worldwide for screening PCAs. Elevation of PSA level above 4 ng/mL indicates 22% probability of PCAs, and a further increase above 10 ng/mL raises the cancer risk to 63%.10 It has been shown that many may harbor PCAs despite low levels of PSA. Several refinements to the standard PSA measurement have been introduced to try and increase the accuracy of prostate-specific cancer identification. These refinements include PSA density (PSA divided by the prostate volume), PSA TZ density (PSA divided by the volume of the TZ), free-to-total PSA ratio (the fraction of unbound serum PSA), and PSA velocity (the rate of change in PSA over time). However, these new refinements have not yet entered into widespread clinical practice.

On **TRUS**, PCa appears as a hypoechoic lesion in the PZ.11 However, many cancers are undetectable, and are presumably isoechoic. Thus, TRUS has poor sensitivity (18.3%) and is also not highly specific.13

**TRUS-guided biopsy** is the current standard of reference for diagnosis of PCAs in a patient who has an abnormal DRE or PSA.14-16 Approximately 20% of patients with an elevated PSA and a negative initial biopsy will have a subsequent positive biopsy, presumably due to sampling error. Also, true Gleason scores may not be represented in the scores obtained due to sampling error. In an effort to improve the results from biopsy, several investigators have advocated routine use of up to 12 biopsies.

**MRI** findings in PCAs were first described in the early 1980s.20 Limitations in evaluating the location, volume, local extent of disease, and the risk of progression by traditional methods of assessment are major roadblocks to improving the management of patients with PCAs. As a result, there is considerable interest in other assessment modalities, particularly MRI.

**TI-weighted** sequences are mainly used (1) for detection of post-biopsy hemorrhage; (2) for evaluation of the contour of the prostate and the status of the NVB, which are well seen in the bright periprostatic fat; and (3) as a baseline sequence for calculation of precontrast T1WI and DCE-MRI for purposes of subtraction.21

The zonal anatomy of the prostate gland is best depicted on high-resolution T2W images. The central zone and TZ cannot be distinguished and are collectively called the central gland. Diffentiation between the two cannot be made by imaging appearances but is based primarily on anatomic location, which is separated from the PZ by a thin pseudocapsule.22 On T2W images, the PZ shows high signal intensity (SI), which is either equal to or more than that of the fat in the vicinity23 and attributed to the fluid-filled ductal and acinar components, with age-related increase in the SI.24 Compared with the PZ, the central gland displays a low or heterogeneous T2 SI since it contains fewer glandular structures and smooth muscles and appears heterogeneous due to the presence of nodules and cysts. The true capsule, seen as a low-intensity rim, is best appreciated on the posterior and posterolateral aspects of the gland. This capsule is an important imaging landmark in PCAs as extracapsular extension (ECE) can upstage the tumor to T3.

**DWI** demonstrates the restriction of diffusion and the reduction of apparent diffusion coefficient (ADC) values in cancerous tissue. This technique allows short acquisition time and provides high contrast resolution between cancer and normal tissue, but individual variability in ADC values may erode diagnostic performance. Using high b-values enhances the DWI sensitivity by reduction of the long T2 relaxation time tissue hyperintensity and therefore cancelling T2 shine-through.25 In our study, we used three b-values (50, 400, and 800), with gradients applied in all three directions. These are the same sequence parameters that were used by Yamamura et al26 and Anwar et al.27

**DCE-MRI** allows assessment of parameters that are useful for differentiating cancer from normal tissue. It allows measurement of the SI of regions of interest (ROI) before arrival of contrast agent (base line) and observes the increase in SI during the wash-in phase and the decrease of SI during the wash-out phase. The advantages of this technique include direct depiction of tumor vascularity and, possibly, obviating of an ERC; however, there also are disadvantages, such as limited visibility of cancer in the TZ. At 1.5 T, DCE-MRI improves

---

**Table 6** Mean ADC values in different prostatic lesions

<table>
<thead>
<tr>
<th>Histopathology</th>
<th>No.</th>
<th>ADC value ($\times 10^{-6}$ mm$^2$/s) mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPH</td>
<td>5</td>
<td>1,142.40 ± 82.60</td>
</tr>
<tr>
<td>Prostatitis</td>
<td>3</td>
<td>1,009.67 ± 161.73</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>36</td>
<td>732.33 ± 160.41</td>
</tr>
<tr>
<td>Microabscess</td>
<td>1</td>
<td>663.00</td>
</tr>
<tr>
<td>Total</td>
<td>45</td>
<td>794.84 ± 206.74</td>
</tr>
</tbody>
</table>

Abbreviations: ADC, apparent diffusion coefficient; BPH, benign prostatic hyperplasia; SD, standard deviation.

---

**Fig. 3** Receiver operating characteristic (ROC) curve for apparent diffusion coefficient (ADC) value.
accuracy, sensitivity, and specificity for PCa detection by 26, 31, and 22%, respectively, relative to T2WI as reported by Kim et al.\textsuperscript{28} Because of overlap of enhancement pattern with benign conditions such as prostatitis in the PZ and BPH nodules in the TZ, DCE-MRI is not considered a dominant imaging sequence in isolation for assessment of cancer, either in the PZ or in the TZ, and is often applied as an adjunct to T2WI and DWI findings in mp-MRI.\textsuperscript{29}

The accuracy of MRS, which depicts a higher ratio of Cho + Cr/Ci in cancerous tissue than in normal tissue, is generally accepted. In stromal BPH, however, citrate and polyamine levels can be strongly suppressed and there may be elevation of choline due to the presence of proliferative elements, leading to significant overlap with the findings of PCa. In addition, prostatitis has previously been found to be able to mimic PCa.\textsuperscript{30} This leads to possible significant difficulty in distinguishing PCa from prostatitis and stromal BPH, especially in the TZ. Moreover, MRS requires a long acquisition time, does not directly depict the periprostatic area, and is frequently affected by artifacts.

\textit{Mp-MRI}, which includes high-resolution T2WI and at least two functional MRI techniques, is the recommended technique of MRI in PCa.\textsuperscript{31} Mp-MRI has shown promising results in diagnosis, localization, risk stratification, and staging of clinically significant PCa. It has also opened up opportunities for focal treatment of PCa. Combinations of T2WI, DWI,
perfusion (DCE-MRI), and spectroscopic imaging have been used in mp-MRI assessment of PCa, but T2 morphologic assessment and functional assessment by diffusion imaging remains the mainstay of PCa diagnosis with mp-MRI. In a diagnostic meta-analysis of seven studies, de Rooij et al revealed a high overall sensitivity and specificity on accuracy of mp-MRI using T2WI, DWI, and DCE-MRI. Pooled sensitivity and specificity were 0.74 and 0.88, respectively, with NPV ranging from 0.65 to 0.94. In another study, mp-MRI showed good performance at detecting and ruling out clinically significant cancer, following at least one previous biopsy, with an NPV of 95% using transperineal template systemic biopsy as the gold standard.

A recently published study reported clinical NPV of mp-MRI at 89.6% for significant cancer over a longitudinal follow-up period of 5 years. Emerging clinical trial data support the adoption of this technology as part of the standard of care for diagnosis of PCa.

Prostate Imaging Reporting and Data System

To expedite clinical evaluation and large-scale implementation of mp-MRI, in May 2010 AdMeTech Foundation’s International Prostate MRI Working Group recommended development of standards of clinical performance by establishing a prostate imaging reporting and assessment system. The European Society of Urogenital Radiology (ESUR) developed consensus-based guidelines for prostate mp-MRI, including clinical indications, minimal and optimal imaging acquisition protocols, and a structured category assessment system known as PI-RADS v1. For PI-RADS v1, it was not specified exactly how to combine the scores from each MRI sequence to derive an overall category assessment. This led to confusion in its application, and variable approaches were used. This contributed to the variability of PI-RADS v1 performance. In early 2012, a joint steering committee of the American College of Radiology, ESUR, and AdMeTech Foundation agreed to collaborate on the development of an improved PI-RADS version 2 (PI-RADS v2). The PI-RADS v2 document was released online in 2015. The PI-RADS scores are the following:

- **PI-RADS 1**: very low (clinically significant cancer is highly unlikely to be present).
- **PI-RADS 2**: low (clinically significant cancer is unlikely to be present).
- **PI-RADS 3**: intermediate (the presence of clinically significant cancer is equivocal).
- **PI-RADS 4**: high (clinically significant cancer is likely to be present).
- **PI-RADS 5**: very high (clinically significant cancer is highly likely to be present).

Current Status of Endorectal Coil for mp-MRI

Many modern 1.5-T MRI scanners do not require an ERC to ensure acceptable image quality. Accordingly, the PI-RADS committee does not prescribe the use of ERC, stating that reliable, satisfactory results can be obtained with both 1.5- and 3-T MRI without the use of an ERC. This position is supported by a systematic review performed by Fusco et al who concluded that new 1.5- and 3-T MRI machines can obtain acceptable image quality without the use of an ERC.

On MRI, *prostatitis* can result in decreased signal in the PZ on both T2WI and the ADC map. Prostatitis may also increase perfusion, resulting in a “false-positive” DCE result. However, the morphology on T2WI is commonly bandlike, wedge-shaped, or diffuse, rather than focal, round, oval, or irregular. ADC values of prostatitis are lower than normal prostate and significantly higher than low- and high-grade PCa. However, due to a very high cell density, granulomatous prostatitis can present itself by ADC values lower than those of PCa. These findings have been reported by Fütterer.
et al.\cite{40} and Bour et al.\cite{41} and was also observed in our single case of chronic granulomatous prostatitis with microabscess (\textit{Fig. 6}). Granulomatous prostatitis, if idiopathic with no supportive clinical history such as Bacillus Calmette-Guerin (BCG) instillation for bladder cancer, tuberculosis, etc., may mimic a PI-RADS 4/5 lesion.\cite{2}

\textit{BPH} is low in SI on T1WI and homogenous/ heterogeneous on T2WI in appearance, ranging from medium to high in SI. Compression of the adjacent PZ results in a low SI band referred to as the surgical pseudocapsule. DWI heterogeneity also manifested as foci of low ADC values interspersed with high ADC values. On T2WI, BPH appears as circumscribed hypointense or heterogeneous encapsulated nodules (PI-RADS 2; \textit{Fig. 6}).

\textit{PZ carcinoma} appears as discrete homogenous low signal focus/mass on T2WI against normally hyperintense PZ and if it is confined to prostate and <1.5 cm, it is scored as PI-RADS 4 (\textit{Fig. 8}). Similar findings with invasive behavior/capsule bulging is scored as PI-RADS 5 (\textit{Figs 9–11}). For the PZ, DWI is the primary determining sequence. Thus, if the DWI score is 4 and T2WI score is 2, the PI-RADS assessment category should be 4.\cite{36}

\textit{The TZ carcinoma} appears as a heterogeneous low signal on T2WI with ill-defined margins to give it an erased charcoal sign, and is scored PI-RADS 4 (\textit{Fig. 12}); if it involves the anterior fibromuscular stroma, then it is lenticular or water drop shaped and is scored PI-RADS 5 (\textit{Fig. 13}). For the TZ, T2WI is the primary determining sequence. Thus, if the T2WI score is 4 and DWI score is 2, then the PI-RADS assessment category should be 4.\cite{36}

Due to the increased cell density, malignancy typically shows restricted diffusion with very low ADC values on the diffusion weighted images. Similar low ADC values were also demonstrated by Zelhof et al.\cite{42} Pickles et al.\cite{43} and Itou et al.\cite{44} in PZ carcinoma and by Turkbey et al.\cite{45} and McNeal et al.\cite{46} in TZ carcinoma.

In our study, the ROC curve was analyzed to compare the performance of ADC in differentiation of cancerous and noncancerous prostatic lesions and statistically significant difference (p-value < 0.0001) was found between them with suggested cutoff criterion of ADC value of <936 × 10–6 mm2/s to predict malignancy. Similar values were also obtained in previous studies by Gibbs et al.\cite{47} and Kim et al.\cite{48} In addition, inverse correlation was observed between Gleason scores and ADC values in pathologically proven cases of cancer (36 cases), that is, lower the value, the higher the grade of tumor, which is in concordance with a previous study by Itou et al.\cite{49}

Tumor localization using T2WI demonstrated overestimation of cancer presence signified by the high sensitivity (80.5%) and low specificity (66.7%). This is most likely due to the difficulty in identifying cancer separately from other benign diseases, leading to a high false-negative rate.

In DCE-MRI, areas demonstrating early, rapid, and intense contrast uptake with subsequent plateau or washout phase were considered suspicious for the presence of malignancy. DCE-MRI alone is very sensitive but has moderate specificity due to significant overlap of early arterial enhancement in nonmalignant conditions like BPH nodules and prostatitis. However, DCE-MRI in the PZ has improved the final PI-RADS score in equivocal cases (\textit{Fig. 14}). Hence, this technique offers diagnostic benefits when compared with conventional MRI alone and as part of a multiparametric prostate MRI examination as suggested by Verma et al.\cite{50}

MRS was optional in initial PI-RADS. However, due to low specificity and additional scanning time required, it has been removed in PI-RADS v2. In our study, too, the final PI-RADS score, which did not take MRS into account, did not miss any positive lesion. However, we continued investigating its role.
at 1.5 T without ERC and our study suggest Cho + Cr/Ci ratio cutoff criterion of >0.89. Cirillo et al.\(^1\) also used a similar ratio of 0.86 as cutoff to differentiate between a benign and a malignant lesion.

**Fig. 8** Peripheral zone carcinoma. (a) T2-weighted axial image showing focal circumscribed area of moderate hypointensity (arrow) in the right peripheral zone. (b) Corresponding area showing restricted diffusion on diffusion weighted imaging (DWI) and hypointensity on apparent diffusion coefficient (ADC) map. (c) Early arterial enhancement on dynamic contrast-enhanced (DCE) imaging noted in the corresponding area (arrow). (d) Magnetic resonance spectroscopy (MRS) shows elevated choline peak and reduced citrate peak with voxel placement in the suspicious area.

**Fig. 9** Peripheral zone carcinoma. (a) T2-weighted axial images show focal area of hypointensity in the right peripheral zone with focal bulge suggesting extracapsular extension. (b) Diffusion weighted imaging (DWI) and corresponding apparent diffusion coefficient (ADC) maps show focal area of restricted diffusion. (c) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) demonstrating focal area of early arterial enhancement. (d) MR spectroscopy reveal elevated choline peak and reduced citrate peak.

**Fig. 10** Prostate cancer with seminal vesicle involvement, bladder base invasion, and bone metastases. (a) T2-weighted (T2W) axial image shows diffuse hypointense signal in both the peripheral zone (PZ) and the transition zone (TZ). (b) T2W axial image showing hypointense signal in the left seminal vesicle (blue arrow) and polypoidal growth in the bladder base. (c) STIR axial image showing multiple focal areas of hyperintense signal in pelvic bones (head of femur—arrow and pubic symphysis). (d) T1FS postcontrast sagittal image showing heterogeneous enhancement of the prostate with involvement of the adjacent bladder base.

**Fig. 11** Prostate cancer with extracapsular extension and involvement of seminal vesicle. (1a) T2-weighted axial image showing hypointense signal in the root of the right seminal vesicle (arrow). (1b) Diffuse hypointense signal in both the transition zone (TZ) and the peripheral zone (PZ) with extracapsular extension (ECE). (2) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) showing early arterial enhancement. (3a) Area of restricted diffusion on diffusion weighted imaging (DWI) with (3b) corresponding hypointensity on apparent diffusion coefficient (ADC) map. (4) Magnetic resonance spectroscopy (MRS) showing raised choline and decrease citrate peak.

**Recommendations of our Study**

Mp-MRI at 1.5 T without ERC can be used for detection of clinically significant PCa.

Recommended cutoffs for malignancy at 1.5 T without ERC from our observations are the following:

- ADC value: \(<9.36 \times 10^{-6} \text{ mm}^2/\text{s}\).
- Cho + Cr/Ci ratio: >0.89.
Limitations of Study

We acknowledge that there may be limitations to our study due to limited number of subjects. As two radiologists analyzed the mp-MRI, interobserver variability is possible. However, the two radiologists who participated in our study have more than 10 and 20 years of clinical experience. Also, we depended mainly on TRUS biopsy; our results need to be supported by additional studies including prostatectomy. Moreover, our study was performed using an external surface coil, which provided limited signal-to-noise ratio with partial volume effects. ERC increases the signal-to-noise ratio by 4 to 10 times and is preferred over external surface coil at 1.5 T.

Conclusion

Mp-MRI at 1.5 T without ERC has shown promising results in diagnosis, localization, characterization, and, to a limited extent, in staging of clinically significant PCa. Combinations of T2WI, DWI, DCE-MRI, and spectroscopic imaging have been used in mp-MRI assessment of PCa, but T2 morphologic assessment and functional assessment by diffusion imaging remain the mainstays of PCa diagnosis with mp-MRI. DCE imaging can be a problem-solving tool in case of equivocal findings on other sequences. Because assessment with mp-MRI can be subjective, use of the newly developed standardized PI-RADS scoring system is helpful for accurate interpretation.

Financial Support and Sponsorship

Nil.

Conflict of Interest

There are no conflicts of interest.

Acknowledgments

We thank Dr. Raj Koticha and Dr. Sayalee Athavale for their contributions.
References

1 Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10(2):63–89
17 Fowler JE Jr, Condon MA, Terrell FL. Cancer diagnosis with prostate specific antigen greater than 10 ng/ml and negative peripheral zone prostate biopsy. J Urol 1996;156(4):1370–1374
35 Hamoen EJH, de Rooy M, Witjes JA, Barentsz JO, Rovers MM. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging; a diagnostic meta-analysis. Eur Urol 2015;67(6):1112–1121
Multiparametric MRI in Evaluating Clinically Significant Prostate Cancer

Ingole et al.


